Top

Published in:

01-02-2016 | Original Article

MiR-378 suppresses prostate cancer cell growth through downregulation of MAPK1 in vitro and in vivo

Authors: Qi-guang Chen, Wei Zhou, Tao Han, Shu-qi Du, Zhen-hua Li, Zhe Zhang, Guang-yi Shan, Chui-ze Kong

Published in: Tumor Biology | Issue 2/2016

Abstract

Prostate cancer is one of the biggest health problems for the aging male. To the present, the roles of dysregulated microRNAs in prostate cancer are still unclear. Here, we evaluated the anti-proliferative role of miR-378 in prostate cancer. And, we found that the expression of miR-378 was significantly downregulated in clinical prostate cancer tissues. In vitro assay suggested that overexpression of miR-378-suppressed prostate cancer cell migration and invasion promoted cell apoptosis. Furthermore, we identified and validated MAPK1 as a direct target of miR-378. Ectopic expression of MAPK1 rescues miR-378-suppressed cell migration and invasion. In vivo assay demonstrated that the stably miR-378-overexpressed prostate cancer cells displayed a significantly reduction in tumor growth. Taken together, our data suggested that miR-378 may act as a potential therapeutic target against human prostate cancer.

Shaikhibrahim Z, Lindstrot A, Ellinger J, Rogenhofer S, Buettner R, Wernert N. Identification of immunity-related genes in prostate cancer and potential role of the ets family of transcription factors in their regulation. Int J Mol Med. 2011;28:799–807.PubMed

Chen WQ, Zheng RS, Zhang SW, Li N, Zhao P, Li GL, et al. Report of incidence and mortality in china cancer registries, 2008. Chin J Cancer Res. 2012;24:171–80.CrossRefPubMedPubMedCentral

Zhang W, Mao YQ, Wang H, Yin WJ, Zhu SX, Wang WC. Mir-124 suppresses cell motility and adhesion by targeting talin 1 in prostate cancer cells. Cancer Cell Int. 2015;15:49.CrossRefPubMedPubMedCentral

Zhang GM, Bao CY, Wan FN, Cao DL, Qin XJ, Zhang HL, et al. Microrna-302a suppresses tumor cell proliferation by inhibiting akt in prostate cancer. PloS One. 2015;10:e0124410.CrossRefPubMedPubMedCentral

Wei Y, Yang J, Yi L, Wang Y, Dong Z, Liu Z, et al. Mir-223-3p targeting sept6 promotes the biological behavior of prostate cancer. Sci Rep. 2014;4:7546.CrossRefPubMedPubMedCentral

Ambros V, Chen X. The regulation of genes and genomes by small rnas. Development. 2007;134:1635–41.CrossRefPubMed

Stegeman S, Moya L, Selth LA, Spurdle AB, Clements JA, Batra J. A genetic variant of mdm4 influences regulation by multiple micrornas in prostate cancer. Endoc Relat Cancer. 2015;22:265–76.CrossRef

Li J, Wan X, Qiang W, Li T, Huang W, Huang S, et al. Mir-29a suppresses prostate cell proliferation and induces apoptosis via kdm5b protein regulation. Int J Clin Exp Med. 2015;8:5329–39.PubMedPubMedCentral

Goto Y, Kurozumi A, Enokida H, Ichikawa T, Seki N. Functional significance of aberrantly expressed micrornas in prostate cancer. Int J Urol. 2015;22:242–52.CrossRefPubMed

10.

Yun SJ, Jeong P, Kang HW, Kim YH, Kim EA, Yan C, et al. Urinary micrornas of prostate cancer: virus-encoded hsv1-mirh18 and hsv2-mir-h9-5p could be valuable diagnostic markers. Int Neurourol J. 2015;19:74–84.CrossRefPubMedPubMedCentral

11.

Xu WT, Jia YJ, Li XJ, Chen J. Micrornas and prostate cancer. Zhonghua Nan Ke Xue. 2015;21:458–62.PubMed

12.

Song C, Chen H, Wang T, Zhang W, Ru G, Lang J. Expression profile analysis of micrornas in prostate cancer by next-generation sequencing. Prostate. 2015;75:500–16.CrossRefPubMed

13.

Nguyen HC, Xie W, Yang M, Hsieh CL, Drouin S, Lee GS, et al. Expression differences of circulating micrornas in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer. Prostate. 2013;73:346–54.CrossRefPubMed

14.

Avgeris M, Stravodimos K, Scorilas A. Loss of mir-378 in prostate cancer, a common regulator of klk2 and klk4, correlates with aggressive disease phenotype and predicts the short-term relapse of the patients. Biol Chem. 2014;395:1095–104.CrossRefPubMed

15.

Mishra S, Deng JJ, Gowda PS, Rao MK, Lin CL, Chen CL, et al. Androgen receptor and microrna-21 axis downregulates transforming growth factor beta receptor ii (tgfbr2) expression in prostate cancer. Oncogene. 2014;33:4097–106.CrossRefPubMed

16.

Avgeris M, Stravodimos K, Fragoulis EG, Scorilas A. The loss of the tumour-suppressor mir-145 results in the shorter disease-free survival of prostate cancer patients. Br J Cancer. 2013;108:2573–81.CrossRefPubMedPubMedCentral

17.

Sun D, Li X, Ma M, Liu J, Xu Y, Ye L, et al. The predictive value and potential mechanisms of mirna-328 and mirna-378 for brain metastases in operable and advanced non-small-cell lung cancer. Jpn J Clin Oncol. 2015;45:464–73.CrossRefPubMed

18.

Li LH, Gao Q, Wang XY, Guo ZJ. mir-378 suppresses hbv-related hepatocellular carcinoma tumor growth by directly targeting the insulin-like growth factor 1 receptor. Zhonghua Gan Zang Bing Za Zhi. 2013;21:609–13.PubMed

19.

Zhang GJ, Zhou H, Xiao HX, Li Y, Zhou T. Mir-378 is an independent prognostic factor and inhibits cell growth and invasion in colorectal cancer. BMC Cancer. 2014;14:109.CrossRefPubMedPubMedCentral

20.

Fei B, Wu H. Mir-378 inhibits progression of human gastric cancer mgc-803 cells by targeting mapk1 in vitro. Oncol Res. 2012;20:557–64.CrossRefPubMed

21.

Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, et al. Mitogen-activated protein (map) kinase pathways: regulation and physiological functions. Endocr Rev. 2001;22:153–83.PubMed

22.

Ganesan J, Ramanujam D, Sassi Y, Ahles A, Jentzsch C, Werfel S, et al. Mir-378 controls cardiac hypertrophy by combined repression of mitogen-activated protein kinase pathway factors. Circulation. 2013;127:2097–106.CrossRefPubMed

23.

Zhang L, Ge Y, Fuchs E. Mir-125b can enhance skin tumor initiation and promote malignant progression by repressing differentiation and prolonging cell survival. Genes Dev. 2014;28:2532–46.CrossRefPubMedPubMedCentral

24.

Huang N, Wang J, Xie W, Lyu Q, Wu J, He J, et al. Mir-378a-3p enhances adipogenesis by targeting mitogen-activated protein kinase 1. Biochem Biophys Res Commun. 2015;457:37–42.CrossRefPubMed

Title: MiR-378 suppresses prostate cancer cell growth through downregulation of MAPK1 in vitro and in vivo
Authors: Qi-guang Chen
Wei Zhou
Tao Han
Shu-qi Du
Zhen-hua Li
Zhe Zhang
Guang-yi Shan
Chui-ze Kong
Publication date: 01-02-2016
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 2/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-015-3996-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2016

The role of microRNAs in the adrenocortical carcinomas

miR-383 inhibits hepatocellular carcinoma cell proliferation via targeting APRIL

MiR-944 functions as a novel oncogene and regulates the chemoresistance in breast cancer

The role of the polycomb repressive complex pathway in T and NK cell lymphoma: biological and prognostic implications

Tubb3 regulation by the Erk and Akt signaling pathways: a mechanism involved in the effect of arginine ADP-ribosyltransferase 1 (Art1) on apoptosis of colon carcinoma CT26 cells

Secreted protein acidic and rich in cysteine enhances the chemosensitivity of pancreatic cancer cells to gemcitabine

Keynote webinar | Spotlight on antibody–drug conjugates in cancer